30
Participants
Start Date
May 2, 2025
Primary Completion Date
January 31, 2031
Study Completion Date
January 31, 2031
Concizumab
Participants will be treated with commercially available Alhemo according to routine clinical practice at the discretion of the treating physician. Administration will be according to the approved product labelling. The decision to treat a participant with Alhemo is made at the physician's discretion before and independently from this study.
Chiba university hospital_Pediatrics, Chiba
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa
Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy, Kawagoe
Nagano red cross hospital_Pediatrics, Nahano
Nanbu Medical Center & Children's Medical Center, Okinawa
Kansai Medical University Hospital_Pediatrics, Osaka
Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy, Saitama
Matsue red cross hospital_Pediatrics, Shimane
National Center for Child Health and Development_Hematology, Tokyo
Lead Sponsor
Novo Nordisk A/S
INDUSTRY